PolyPid Ltd. (PYPD) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
6.61
↑+36% vs avg
5yr avg: 4.86
30Y Low2.3·High6.5
ROE
↓
-366.3%
↓+38% vs avg
5yr avg: -589.5%
30Y Low-366%·High-22%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PYPD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
PolyPid Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $81M | $71M | $18M | $5M | $27M | $215M | $379M | — | — | — | — |
| Enterprise Value | $77M | $67M | $12M | $12M | $32M | $205M | $375M | — | — | — | — |
| P/E Ratio → | -2.12 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 6.61 | 6.47 | 2.34 | — | 4.65 | 5.98 | 5.21 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PYPD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
PYPD Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -366.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -366.3% | -366.3% | -1038.7% | -1278.6% | -189.2% | -74.9% | -68.1% | -22.3% | — | — | — |
| ROA | -143.8% | -143.8% | -143.0% | -115.4% | -112.6% | -67.8% | -64.5% | -28.6% | 31.6% | -258.1% | -104.9% |
| ROIC | -547.8% | -547.8% | -733.2% | -227.4% | -157.0% | -68.4% | -41.3% | — | — | — | — |
| ROCE | -243.2% | -243.2% | -271.8% | -179.3% | -145.2% | -79.1% | -50.4% | -88.4% | -120.8% | -74.3% | -111.8% |
PYPD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $6M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.25 | 0.25 | 1.25 | — | 2.36 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.33 | -0.78 | — | 0.89 | -0.27 | -0.06 | -0.13 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -18.38 | -13.36 | -29.04 | — | -1545.41 | -1237.33 | -437.24 | -862.50 | -94.99 |
Net cash position: cash ($6M) exceeds total debt ($3M)
PYPD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.97x means PolyPid Ltd. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 0.83x to 1.97x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.97 | 1.97 | 1.31 | 0.83 | 1.66 | 4.31 | 16.41 | 10.63 | 2.18 | 5.57 | 10.75 |
| Quick Ratio | 1.82 | 1.82 | 1.31 | 0.83 | 1.66 | 4.31 | 16.41 | 10.49 | 2.18 | 5.57 | 10.75 |
| Cash Ratio | 1.67 | 1.67 | 1.23 | 0.77 | 1.47 | 3.99 | 15.46 | 10.32 | 1.99 | 5.33 | 10.45 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 2.70 | — | — | — | — | — | — | 2.70 | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
PYPD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
PolyPid Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $16M | $6M | $1M | $1M | $1M | $1M | $886430 | $886430 | $588148 | $588148 |
Peer Comparison
Compare PYPD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PYPDYou | $81M | -2.1 | — | — | — | — | -366.3% | -547.8% | — |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 ACRS | $586M | -9.2 | — | — | 73.3% | -975.9% | -50.2% | -53.5% | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 CLDX | $2B | -8.5 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 MRK | $277B | 15.4 | 10.7 | 22.4 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 BMY | $115B | 16.3 | 9.2 | 8.9 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 IQV | $30B | 22.8 | 13.0 | 14.8 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See PYPD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PYPD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PYPD vs AGIO
Side-by-side business, growth, and profitability comparison vs Agios Pharmaceuticals, Inc..
Start ComparisonPYPD — Frequently Asked Questions
Quick answers to the most common questions about buying PYPD stock.
What is PolyPid Ltd.'s P/E ratio?
PolyPid Ltd.'s current P/E ratio is -2.1x. This places it at the 50th percentile of its historical range.
What is PolyPid Ltd.'s ROE?
PolyPid Ltd.'s return on equity (ROE) is -366.3%. The historical average is -144.2%.
Is PYPD stock overvalued?
Based on historical data, PolyPid Ltd. is trading at a P/E of -2.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.